TCS Industries Limited (China-sourced API supplier) supplies Lomustine — API CAS 13010-47-4 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Lomustine |
|---|---|
| Structural Formula |  |
| CAS Number | 13010-47-4 |
| Molecular Formula | C9H16ClN3O2 |
| Molecular Weight | 233.69 g/mol |
| InChIKey | GQYIWUVLTXOXAJ-UHFFFAOYSA-N |
| SMILES | Available on request where applicable |
| Appearance | Yellow powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Store at 2–8°C |
Lomustine (CAS 13010-47-4, CCNU) is a nitrosourea alkylating agent with the formula C₉H₁₆ClN₃O₂ (MW 233.70). It is a lipophilic compound that crosses the blood-brain barrier, making it effective against CNS tumors. Lomustine is used for brain tumors (glioblastoma, medulloblastoma), Hodgkin lymphoma, and is on the WHO Model List of Essential Medicines.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Lomustine API in pharmaceutical grade for global procurement programs.
> Applications
CNS tumor chemotherapy
Lomustine alkylates DNA through chloroethyl carbonium ion intermediates and carbamoylates proteins, causing inter-strand DNA cross-links. Its high lipophilicity enables blood-brain barrier penetration. It is administered orally at 100–130 mg/m² every 6 weeks as a single dose for glioblastoma (often combined with temozolomide and radiation). Herrlinger et al. (Lancet, 2019, 393:678–688) demonstrated that lomustine plus temozolomide improved overall survival compared to temozolomide alone in newly diagnosed glioblastoma with MGMT promoter methylation.
Hodgkin lymphoma
Lomustine is used in combination chemotherapy regimens (MOPP variant, CEPP) for relapsed Hodgkin lymphoma. Its oral administration, single-dose schedule, and non-overlapping toxicity profile with other agents make it suitable for combination regimens.
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Lomustine with buyers in Australia, New Zealand, Canada and South Korea.
- Evaluation and commercial quantities: 10 g samples for analytical qualification; 100 g and 1 kg for production. Cytotoxic API — requires dedicated handling facilities. DMF reference letters available.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥97.0%), related substances (trans-4-hydroxylomustine, total ≤2.0%), loss on drying, residual solvents, heavy metals, and microbial limits. Yellow powder. Soluble in ethanol and acetone, slightly soluble in water. Melting point 89–92 °C. Identity by HPLC, IR, and melting point. Handle as cytotoxic material. Meets USP and in-house pharmaceutical specifications. COA and MSDS are standard.
> Packaging
Lomustine is a yellow powder, cytotoxic — must be handled with appropriate containment measures. Standard packaging includes double-sealed aluminium foil bags in rigid containers (100 g or 1 kg). Store at 2–8 °C. Protect from light. Cytotoxic substance labeling and handling precautions apply. Shelf life is typically 24 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Lomustine is FDA-approved (CeeNU/Gleostine) for brain tumors and Hodgkin lymphoma. EMA-authorized. On the WHO Model List of Essential Medicines. Generic lomustine capsules available. Manufacturing requires cytotoxic API handling facilities. DMF support available from qualified manufacturers.
> Alias Index
- INN: Lomustine
- CAS Number: 13010-47-4
- Formula: C₉H₁₆ClN₃O₂ (MW 233.70)
- Abbreviation: CCNU (N-(2-chloroethyl)-N’-cyclohexyl-N-nitrosourea)
- Brand names: CeeNU, Gleostine
- ATC code: L01AD02
- Related: Carmustine (BCNU), Semustine (MeCCNU)
- Commercial request terms: lomustine API, CCNU bulk, CeeNU generic, nitrosourea alkylating agent, TCS Industries Limited
> FAQ
Why does Lomustine cross the blood-brain barrier?
Lomustine is a small (MW 233.70), highly lipophilic molecule with a log P of approximately 2.9. It crosses the BBB by passive diffusion through lipid bilayer membranes. Peak CNS concentrations occur 30–60 minutes after oral dosing. This property makes nitrosoureas uniquely valuable for CNS tumor chemotherapy where most other alkylating agents are excluded.
What documents are available for Lomustine orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Lomustine to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
Why is dosing every 6 weeks?
Lomustine causes delayed, cumulative myelosuppression (nadir at 4–6 weeks). The 6-week dosing interval allows bone marrow recovery between cycles. WBC and platelet counts must be checked before each dose. Dose reduction is required for cumulative myelotoxicity. This schedule also reflects the drug delayed DNA damage mechanism.
What cytotoxic handling is required?
Lomustine is a cytotoxic/genotoxic compound. API manufacturing and formulation require containment facilities (OEB 4/5, OEL <1 μg/m³). Personnel must use protective equipment. Environmental monitoring, decontamination procedures, and waste disposal must follow cytotoxic material handling guidelines. TCS sources from manufacturers with appropriate containment capabilities.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Lomustine packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
Is MGMT methylation testing relevant?
Yes. MGMT promoter methylation predicts response to alkylating agents including lomustine. Patients with MGMT-methylated glioblastoma benefit from lomustine + temozolomide combination. MGMT-unmethylated tumors show reduced benefit from alkylating chemotherapy. Biomarker testing guides treatment selection.
Last reviewed: June 2026
Evaluation and research orders (≤10 kg) are shipped with COA, MSDS, and certificate of origin. Bulk commercial orders (>10 kg) qualify for volume pricing with a full technical documentation package available on request.
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.